{"id":58574,"date":"2023-12-13T07:04:26","date_gmt":"2023-12-13T06:04:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sofinnova-partners-launches-biovelocita-the-first-pan-european-investment-strategy-dedicated-to-the-creation-and-acceleration-of-biotech-startups\/"},"modified":"2023-12-13T07:04:26","modified_gmt":"2023-12-13T06:04:26","slug":"sofinnova-partners-launches-biovelocita-the-first-pan-european-investment-strategy-dedicated-to-the-creation-and-acceleration-of-biotech-startups","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sofinnova-partners-launches-biovelocita-the-first-pan-european-investment-strategy-dedicated-to-the-creation-and-acceleration-of-biotech-startups\/","title":{"rendered":"Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups"},"content":{"rendered":"
\n

\nExperienced team of serial entrepreneurs and investors will partner with leading academic institutions to identify the most innovative ideas and create the biotech champions of tomorrow<\/i><\/p>\n

PARIS–(BUSINESS WIRE)–#VC<\/a>—Sofinnova Partners<\/a> (\u201cSofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita<\/a>, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.<\/p>\n

<\/a>
<\/a><\/p>\n

\nBiovelocita\u2019s newly formed team will provide a hands-on, robust framework for startups, combining direct management, financial backing, and access to Sofinnova\u2019s extensive infrastructure and network. The strategy builds upon Sofinnova\u2019s established track record of nurturing innovative ventures within the healthcare and sustainability sectors. It draws inspiration from the achievements of Italy\u2019s first biotech accelerator, BiovelocITA, co-founded by Gabriella Camboni, Silvano Spinelli and Sofinnova Partners in 2015, which has significantly contributed to the growth of the Italian biotech ecosystem.<\/p>\n

\nGraziano Seghezzi, Managing Partner of Sofinnova Partners<\/b>, said: \u201cWith Sofinnova Biovelocita, we are doubling down on our commitment to innovation and company creation in the life sciences. To improve and expand our company-creation toolbox, we have brought together a group of experienced investors and entrepreneurs who have been collaborating with Sofinnova for over a decade, some nearly two decades. With this top-tier team, we look forward to strengthening one of Sofinnova\u2019s strategic pillars: acceleration, which is already making rapid strides in the medical device space with Sofinnova MD Start, our in-house medtech accelerator.\u201d<\/p>\n

\nKey partners of this initiative include:<\/p>\n